Beyond Borders: What The Global Cell Therapy Community Can Learn From China's Rise

By Andy Lamb, VP Global Commercial Strategy, CellBri

As geopolitics increasingly influences biotechnology supply chains and domestic manufacturing policies, the global advanced therapy sector faces a pivotal moment. While nations focus on building regional resilience, isolating regional innovations risks slowing therapeutic progress. In cell therapy, rapid advancement in China demonstrates how simultaneous investments in translational research, manufacturing infrastructure, and process innovation can significantly compress development timelines. Addressing the steep cost of autologous treatments requires streamlining workflows through digital integration, standardized procedures, and automation to lower the cost per patient. True progress relies on evaluating global best practices rather than isolating regional ecosystems. By combining international regulatory rigor, commercialization expertise, and manufacturing efficiency, the industry can accelerate patient access worldwide. Read the full article to explore strategies for global collaboration and manufacturing optimization.